Irinotecanhydrochloridetrihydraat Hikma 20 mg/ml clinical trials

Neo-adjuvant intraperitoneal chemotherapy (irinotecan) and systemic chemotherapy (mFOLFOX4-bevacizumab) prior to CRS-HIPEC for patients with isolated resectable colorectal peritoneal metastases: a multicentre, phase II trial (INTERACT-PLUS)

This study looks at new ways to treat bowel cancer that has spread to the lining of the tummy. It tests a combination of medicines given before surgery to see if it helps patients. The goal is to improve treatment for this type of cancer.